Menu
Back to User profile » Dr Giuliano Rizzardini
Papers published by Dr Giuliano Rizzardini:
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D
Therapeutics and Clinical Risk Management 2017, 13:787-797
Published Date: 29 June 2017
Impact and differential clinical utility of cobicistat-boosted darunavir in HIV/AIDS
Cossu MV, Astuti N, Capetti A, Rizzardini G
Virus Adaptation and Treatment 2015, 7:47-56
Published Date: 21 August 2015
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort
Tontodonati M, Cenderello G, Celesia BM, Trezzi M, Ursini T, Costantini A, Marra D, Polilli E, Catalani C, Butini L, Sozio F, Mazzotta E, Sciacca A, Rizzardini G, Manzoli L, Cozzi-Lepri A, Parruti G
ClinicoEconomics and Outcomes Research 2015, 7:27-35
Published Date: 22 December 2014
Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
Restelli U, Andreoni M, Antinori A, Bonfanti M, Di Perri G, Galli M, Lazzarin A, Rizzardini G, Croce D
ClinicoEconomics and Outcomes Research 2014, 6:409-414
Published Date: 23 September 2014
Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy
Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL
Therapeutics and Clinical Risk Management 2012, 8:377-384
Published Date: 17 September 2012
Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?
Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Foglia E, Carenzi L, Croce D
ClinicoEconomics and Outcomes Research 2012, 4:245-252
Published Date: 5 September 2012